American Journal of Cardiology
Volume 105, Issue 1 , Pages 100-104 , 1 January 2010

Baseline Low-Density Lipoprotein Cholesterol Levels and Outcome in Patients With Heart Failure

  • Gideon Charach, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author: Tel: 972-3-6973766; fax: 972-3-6974990
    • ,
  • Jacob George, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Arie Roth, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Ori Rogowski, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Dov Wexler, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • David Sheps, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Itamar Grosskopf, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Moshe Weintraub, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Gad Keren, MD

      Affiliations

    • Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Ardon Rubinstein, MD

      Affiliations

    • Department of Internal Medicine “C”, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Received 26 December 2008 ,Revised 12 August 2009 ,Accepted 12 August 2009.

References 

  1. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–1486
  2. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman T, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler Suppl. 2004;5:81–87
  3. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern?. Am Heart J. 2006;152:39–49
  4. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure (Beyond the lipid lowering effect). Int J Cardiol. 2007;115:144–150
  5. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail. 2006;12:664–674
  6. Sakatani T, Shirayama T, Suzaki Y, Yamamoto T, Mani H, Kawasaki H, et al. The association between cholesterol and mortality in heart failure (Comparison between patients with and without coronary artery disease). Int Heart J. 2005;46:619–629
  7. Domanski M, Coady S, Fleg J, Tian X, Sachdev V. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007;99:1448–1450
  8. von Haeling S, Okonko DO, Anker SD. Statins: a treatment option for chronic heart failure?. Heart Fail Monit. 2004;4:90–97
  9. Krum H, McMurray J. Statins and chronic heart failure: do we need a large-scale outcomes trial?. J Am Coll Cardiol. 2002;39:1567–1573
  10. Krum H, Latini R, Maggioni A, Anand I, Masson S, Carretta E, et al. Statins and symptomatic chronic systolic heart failure: a post hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119:48–53
  11. Go A, Lee W, Yang J, Lo GC, Gurwitz JH. Statin therapy and risk for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105–2111
  12. Krum H, Ashton E, Reid C, Kalff V, Rogerd J, Amarena J, et al. Double-blind, randomized, placebo-controlled study of high dose HMG COA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic heart failure. J Card Fail. 2007;13:1–7
  13. Bohm M, Hjalmarson A, Kjeksus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins—why do we need a clinical trial?. Z Kardiol. 2005;94:223–230
  14. Rauchhaus M, Clarc AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933–1940
  15. Clearfield M. Rosuvastatin in older patients with systolic heart failure. Curr Atheroscler Rep. 2009;11:5–68
  16. Alehagen U, Lindshtedt G, Levin L, Dahistrom U. The risk of cardiovascular death in elderly patients with possible heart failure (Results from 6-year follow-up of Swedish primary care population). Int J Cardiol. 2005;100:17–27
  17. Horwich TB, Hamilton M, Maclellan W, Fonarew GC. Low total serum cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216–224
  18. Iwaoka M, Obata JE, Abe M, Nakamura T, Kitta Y, Kodama Y, et al. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail. 2007;13:247–253
  19. Aronov SW, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:147–149
  20. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J. 2006;152:1077–1083
  21. Richartz BM, Radovancevic B, Frazier OH, Vaughn WK, Taegtmeyer H. Low serum cholesterol levels predict high perioperative mortality in patients supported by left ventricular assist system. Cardiology. 1998;89:184–188
  22. Fraunberger P, Nagel D, Walli AK, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med. 2000;28:3574–3575
  23. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–459
  24. Schatz U, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all cause mortality in elderly people from Honolulu Heart Program: a cohort study. Lancet. 2001;358:351–355
  25. Tikhonoff V, Casiglia E, Mazza A, Scarpa R, Thijs L, Pessina AC, et al. Low-density lipoprotein cholesterol and mortality in older people. J Am Geriatr Soc. 2005;53:2159–2164
  26. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and effect of valsartan. Circulation. 2005;112:1428–1434
  27. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from Vesnarinone Trial (VEST). Circulation. 2001;103:2055–2059
  28. Harris HW, Grunfeld C, Feingold KR, Rapp JH. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest. 1990;86:696–702
  29. Christ M, Klima T, Grimm W, Mueller HH, Maisch B. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2006;27:691–699

PII: S0002-9149(09)02225-5

doi: 10.1016/j.amjcard.2009.08.660

American Journal of Cardiology
Volume 105, Issue 1 , Pages 100-104 , 1 January 2010

Article Tools

* Image Usage & Resolution